New Major Order From China

STOCKHOLM, Sept. 29, 2019 /PRNewswire/ — Bactiguard has received a new order from Well Lead Medical (Well Lead) in China. The order will be delivered promptly and generate revenues in the third quarter of approximately SEK 4,8 million.

“The order we have just received from Well Lead is the first outside of the initial contract and therefore an important milestone in our cooperation, as it shows that end-customer sales in China are picking up”, says Christian Kinch, CEO.

In June 2018, Bactiguard signed a combined distribution and license agreement with Well Lead, China’s leading manufacturer of consumable medical devices.

The first two product orders, at a combined value of SEK 20 million, were part of the initial contract and delivered in the second and fourth quarters of 2018. The third order, which has now been received, is worth SEK 4,8 million and it is the first order outside the initial contract.

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2019-09-29, at 20:00

For further information, please contact:

Cecilia Edström
CFO and deputy CEO
mobile: +46-722-262-328

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/bactiguard-holding-ab–publ-/r/new-major-order-from-china,c2920728

The following files are available for download:

https://mb.cision.com/Main/9686/2920728/1115431.pdf

190929 New major order from China

View original content:http://www.prnewswire.com/news-releases/new-major-order-from-china-300927429.html

SOURCE Bactiguard Holding AB (publ)

user

Recent Posts

RESPIREE SECURES SINGAPORE HSA APPROVAL FOR ITS AI-ENABLED 1BIO™AI SOFTWARE TO SUPPORT ACUTE DETERIORATION DETECTION

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- AI/ML health-tech startup Respiree has received approval from the Health…

35 minutes ago

AI-for-Science Startup ChemLex Raises USD 45M, Launching Self-Driving Lab for Drug Discovery in Singapore

SINGAPORE, Dec. 7, 2025 /PRNewswire/ -- ChemLex, a next-generation AI-for-science company, today announced the establishment…

35 minutes ago

Is The DEA in Systemic Collapse: Corruption, Constitutional Violations, and a Seven-Year War Against Marijuana Medical Science

The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…

16 hours ago

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…

16 hours ago

Secura Bio Presents Extended Follow Up Analyses from Phase 2 PRIMO Trial in Patients with Relapsed/Refractory peripheral T-cell lymphoma at the 2025 American Society of Hematology Meeting

Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…

16 hours ago